Ipilimumab (Yervoy®) is the first immune checkpoint agent, approved for the treatment of melanoma, which acts by blocking the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and re-activating T cells. The gene discussed is CTLA4; the disease is melanoma.